Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500942 | 1.00 | HSD11B1 (0.41) | HSD11B1EPHX2CXCR3HCAR1P2RX7 | |
| SCHEMBL3880991 | 1.00 | HSD11B1 (0.41) | HSD11B1EPHX2CXCR3HCAR1P2RX7 | |
| SCHEMBL5121910 | 0.85 | HSD11B1 (0.59) | HSD11B1EPHX2CXCR3FFAR1 | |
| SCHEMBL3880099 | 0.82 | P2RX7 (0.37) | HSD11B1P2RX7 | |
| SCHEMBL2993740 | 0.81 | SIGMAR1 (0.42) | HSD11B1CXCR3P2RX7ALDH1A1 | |
| SCHEMBL2993742 | 0.81 | SIGMAR1 (0.42) | HSD11B1CXCR3P2RX7ALDH1A1 | |
| SCHEMBL2993737 | 0.81 | SIGMAR1 (0.42) | HSD11B1CXCR3P2RX7ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2999277 | 0.81 | P2RX7 (0.37) | HSD11B1P2RX7 | |
| SCHEMBL4513611 | 0.80 | HSD11B1 (0.46) | HSD11B1HCAR1 | |
| SCHEMBL4513608 | 0.80 | HSD11B1 (0.46) | HSD11B1HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885EPHX2 670/4885CXCR3 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.